

Agile Therapeutics Third Quarter 2022 Earnings Call

November 7, 2022

Forward-Looking Statements


Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla[®], the potential market acceptance and uptake of Twirla[®], including the increasing demand for Twirla in the fourth quarter of 2022 and in 2023, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV (CTV) campaign and its ability to promote growth, our prospects for future financing arrangements, our expected operating expenses for the fourth quarter of 2022, and our financial condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully enhance the commercialization of and increase the uptake for Twirla, the size and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candidates, the effects of the ongoing COVID-19 pandemic on our commercialization efforts, clinical trials, supply chain, operations and the operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on our potential customer base, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

3Q 2022 Performance Update


Q3 2022 Net Revenue Growth

	Q3 2022	Q2 2022	% Change
Net Revenue (vs. Q2 2022)	\$3.0M	\$2.1M	+43%
	Q3 2022	Q3 2021	% Change
Net Revenue (vs. Q3 2021)	\$3.0M	\$1.3M	+131%

Twirla Demand: Retail vs. Non-Retail (Quarterly)



Consecutive Quarters of Accelerated Factory Sales Growth (Cycles) and Reduced Non-GAAP OPEX



Q3 2022 Results: Business Plan is Performing

	Q3 2022 vs. Q2 2022			Q3 2022 vs. Q3 2021	
	Q3 2022	Q2 2022	% Change	Q3 2021	% Change
Net Revenue	\$3.0M	\$2.1M	+43%	\$1.3M	+131%
Non-GAAP OPEX	\$9.2M	\$11.3M	-19%	\$14.4M	-36%
	YTD 2022 vs. YTD 2021				
	Thru Sept. 30, 2022	Thru Sept. 30, 2021	% Change		
Net Revenue	\$6.9M	\$2.6M	+165%		
Non-GAAP OPEX	\$36.3M	\$46.3M	-22%		

Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and elsewhere in this presentation.

Twirla Business Plan Update

Twirla Business Plan: Non-Retail Channel Growth Driver



The graphic features a white circle with a purple outline. Inside the circle, the Afaxys logo is displayed in blue and green, with the tagline "affordable access®" below it. Below the Afaxys logo is the Planned Parenthood logo, which includes a stylized 'P' icon and the text "Planned Parenthood®".

- From the end of the second quarter 2022 to the end of the third quarter 2022, **non-retail cycles purchased grew 361% (1,404 to 6,479).**
- **Growth driven by Afaxys-led promotion to the Planned Parenthood network.**
- Third quarter included **conversion of Planned Parenthood accounts in California**

Twirla Business Plan: Additional Upside Potential for 4Q22 and 2023



Twirla CTV Commercial



Telemedicine



Afaxys Collaboration

Finance Update

Q&A

Closing Remarks

Reconciliation of Non-GAAP Financial Measures (unaudited)

	Three Months Ended					Nine Months Ended September 30,	
	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	2022	2021
GAAP Operating expenses	\$20,285	\$11,293	\$15,807	\$18,170	\$14,350	\$47,383	\$46,217
Non-GAAP adjustment: Loss on disposition of assets	\$11,122	-	-	-	-	\$11,122	-
Non-GAAP operating expenses	\$ 9,163	\$11,293	\$11,293	\$11,293	\$14,350	\$36,261	\$46,217